治疗鳞状非小细胞肺癌新药——表皮生长因子受体阻滞剂necitumumab

New drug for therapy in squamous non-small cell lung cancer—epidermal growth factor receptor blocker necitumumab

表皮生长因子受体(EGFR)在多种实体瘤中表达,与肿瘤的发生和发展密切相关。necitumumab为一全人源化IgG1_κ单克隆抗体,与表皮生长因子竞争结合部位,阻滞表皮生长因子与其受体结合,抑制EGFR依赖性肿瘤的生长。necitumumab已获美国食品和药物管理局批准联合吉西他滨和顺铂用于转移性鳞状非小细胞肺癌的一线治疗。常见的不良反应包括皮疹、呕吐、腹泻、皮炎及电解质紊乱等。

The epidermal growth factor receptor （EGFR） is expressed in a variety of solid tumours and has been implicated in promoting oncogenesis and turnout progression. Necitumumab is an fully human IgG1k monoclonal antibody. It can compete with human EGFR for binding site and block the binding of ligands, so that it can inhibit EGFR-dependent tumour cells. Necitumumab was approved by the United States Food and Drug Administration for therapy of metastatic squamous non-small cell lung cancer. The most common adverse event of necitumumab were rash, vomiting, diarrhoea, dermatitis acneiform, electrolyte abnormalities and so on.